India to relaunch “Jan Aushadi” (medicines for all) generics scheme

26 May 2015
gateway-of-india-big

The Indian government's plan to open around 5,000 low-cost medical stores and pharmacies across the country appears to have been given a fresh lease of life, with a pilot scheme set to relaunch the sale of cheap, and in some cases free, generic drugs across six states, reports The Pharma Letter’s India correspondent.

First launched in 2008, the Jan Aushadi scheme (medicines for all) that aims at making medicines more affordable across the country, was stillborn with only 98 stores in operation out of the initial 178 functional stores. The initiative will establish special pharmacies that are licensed by the government, to promote the use of inexpensive generic medicines.

The pharmacy chains would sell generic drugs like cardiovasculars, antibiotics, anti infective and gastrointestinals at prices that are at over 50% discount to branded drugs.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Generics